- Almirall SA
- Eli Lilly & Co.
- Pfizer Inc.
- Boehringer Ingelheim International GmbH
- Altana AG
- Fougera Pharmaceuticals Inc.
- Forest Laboratories Inc.
- Meda AB
- Novartis AG
- Vectura Group PLC
- GlaxoSmithKline PLC
- Innoviva Inc.
- Johnson & Johnson
- Paion AG
- Cardiovascular Systems Inc.
- Reckitt Benckiser Group PLC
- Shire PLC
- AstraZeneca PLC
- Pharmion Corp.
- Sumitomo Dainippon Pharma Co. Ltd.
- GW Pharmaceuticals PLC
- Pierre Fabre Group
- Gilead Sciences Inc.
- Celgene Corp.
- Cephalon Inc.
- Alkermes PLC
- Genzyme Corp.
- Ionis Pharmaceuticals Inc.
- Vectura Group PLC
- Almirall completes €102mm flotation on Spanish market
- Ipsen grosses €324mm in IPO
- Nycomed is buying Altana's pharma business for €4.5bn
- Almirall licenses COPD agent to Forest
- Almirall is buying Meda's inhaler business
- Novartis gets rights to Arakis and Vectura's AD237
- GSK, Theravance develop respiratory drug candidates
- Pharmacia/Almirall's migraine deal terminated
- Ortho-McNeil will market Almirall's Axert
- Forest,Paion end stroke collaboration
- Forest Labs,Replidyne terminate US faropenem medoxomil deal
- Almirall buys Hermal from Reckitt Benckiser for £255mm
- Shire divests eight non-core products to Almirall
- Meda acquires Viatris for €750mm
- Almirall licenses European rights to GW's Sativex
- AZ and BMS enter Type II diabetes deal; BMS later sells diabetes business to AZ
- BMS, Pfizer work together on Phase III antithrombotic
- Pfizer gives BMS rights to early-stage metabolic projects
- Cephalon, Alkermes sell Vivitrex in US; ends
- Degusssa AG sells off Viatris unit in LBO
- BI, Vectura develop inhaler for respiratory diseases; ends
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. firstname.lastname@example.org.
All fields are required.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.